Advertisement
Singapore markets closed

  • Straits Times Index

    3,306.02
    +6.02 (+0.18%)
     

  • Nikkei

    38,596.47
    -36.55 (-0.09%)
     

  • Hang Seng

    18,028.52
    -306.80 (-1.67%)
     

  • FTSE 100

    8,237.72
    -34.74 (-0.42%)
     

  • Bitcoin USD

    64,487.12
    +215.00 (+0.33%)
     

  • CMC Crypto 200

    1,351.16
    -9.17 (-0.67%)
     

  • S&P 500

    5,464.62
    -8.55 (-0.16%)
     

  • Dow

    39,150.33
    +15.57 (+0.04%)
     

  • Nasdaq

    17,689.36
    -32.23 (-0.18%)
     

  • Gold

    2,334.70
    -34.30 (-1.45%)
     

  • Crude Oil

    80.59
    -0.70 (-0.86%)
     

  • 10-Yr Bond

    4.2570
    +0.0030 (+0.07%)
     

  • FTSE Bursa Malaysia

    1,590.37
    -2.32 (-0.15%)
     

  • Jakarta Composite Index

    6,879.98
    +60.66 (+0.89%)
     

  • PSE Index

    6,158.48
    -186.08 (-2.93%)
     

Here's What Key Metrics Tell Us About Deciphera Pharmaceuticals (DCPH) Q1 Earnings

Zacks Equity Research
·2-min read

Deciphera Pharmaceuticals, Inc. (DCPH) reported $45 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 34.5%. EPS of -$0.52 for the same period compares to -$0.60 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $45.99 million, representing a surprise of -2.15%. The company delivered an EPS surprise of +5.45%, with the consensus EPS estimate being -$0.55.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

ADVERTISEMENT

Here is how Deciphera Pharmaceuticals performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Product revenues, net- Rest of world: $10.71 million versus $10.77 million estimated by two analysts on average.

  • Product revenues, net- U.S. $31.84 million versus $33.68 million estimated by two analysts on average.

  • Collaboration revenues: $2.45 million versus the seven-analyst average estimate of $1.24 million.

  • Product revenues, net: $42.55 million versus the seven-analyst average estimate of $44.75 million. The reported number represents a year-over-year change of +28.1%.

View all Key Company Metrics for Deciphera Pharmaceuticals here>>>

Shares of Deciphera Pharmaceuticals have returned +63.5% over the past month versus the Zacks S&P 500 composite's +0.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research